Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. [electronic resource]
Producer: 20110825Description: 224-6 p. digitalISSN:- 1097-6787
- Absorptiometry, Photon
- Administration, Oral
- Antineoplastic Agents -- administration & dosage
- Benzamides
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Imatinib Mesylate
- Mastocytosis, Systemic -- complications
- Middle Aged
- Osteolysis -- complications
- Piperazines -- administration & dosage
- Pyrimidines -- administration & dosage
- Risk Assessment
- Severity of Illness Index
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Letter
There are no comments on this title.
Log in to your account to post a comment.